NCT06052566View on ClinicalTrials.gov

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Non-alcoholic SteatohepatitisHepatic Impairment
Interventions
DRUG

Efinopegdutide

Subcutaneous injection administered at a dose of 7 mg

Trial Locations (4)

33147

Advanced Pharma CR, LLC ( Site 0001), Miami

33603

Genesis Clinical Research, LLC ( Site 0006), Tampa

78215

American Research Corporation ( Site 0002), San Antonio

33014-3616

Clinical Pharmacology of Miami ( Site 0005), Miami

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06052566 - A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) | Biotech Hunter | Biotech Hunter